CLINICAL_TRIALS
trial_result
· 2021-10-11
Clinical Trial Update: Effects of PCSK9 Inhibition by Evolocumab on Postprandial Lipid Metabolism in Type 2 Diabetes [Phase 4]
Summary
Phase 4 trial evaluating the effects of PCSK9 inhibition with evolocumab on postprandial lipid metabolism in patients with type 2 diabetes.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Marja-Riitta Taskinen | Conditions: Type 2 Diabetes Mellitus | Phase 4 | Status: COMPLETED | Results posted: 2021-10-11